Cell and gene therapies: The latest developments in viral and non-viral vector manufacturing
In 2018 alone, 70% of regenerative medicine companies around the globe had deployed vectors in products under investigation. AAV and lentivectors are the most common vectors of choice in FDA-approved gene and cell therapy products, including Gilead's Yescarta and Novartis' Kymriah.
In light of the increasing demand, we take a look into the latest developments and opportunities in viral and non-viral vector manufacturing for cell and gene therapies.
